ACLCX Performance — Value Fund, C Class
Data updated: 2026-08-28
ACLCX returned +11.10% year to date and +22.02% over one year to Jun 2026. Annualised returns are +13.14% over 3 years and +8.90% over 5 years. The fund beat its US Multi-Cap Value category average: $100 invested three years ago grew to $145, against $142 for the category, and to $122 over one year, against $112. Volatility over the past three years was 11.69% a year. In the 12 months to Jun 2026 the fund lost a net $496.8M, and assets reached $1.89B.
ACLCX Growth of $100
What $100 invested in Value Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Multi-Cap Value category average over the same months.
| Period | ACLCX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $122 | $112 |
| 3 years (Jul 2023 – Jun 2026) | $145 | $142 |
| 5 years (Jul 2021 – Jun 2026) | $153 | $143 |
| Since data start (Jul 2019 – Jun 2026) | $198 | $188 |
ACLCX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +11.10% |
| 1 year | +22.02% |
| 3 years (annualised) | +13.14% |
| 5 years (annualised) | +8.90% |
ACLCX Annual Returns
Calendar-year total returns of Value Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +11.10% |
| 2025 | +14.54% |
| 2024 | +7.99% |
| 2023 | +7.72% |
| 2022 | −0.85% |
| 2021 | +23.08% |
| 2020 | −0.47% |
| 2019 (Jul–Dec) | +9.89% |
ACLCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.2% | +4.5% | −5.6% | +4.4% | +0.8% | +2.6% | — | — | — | — | — | — |
| 2025 | +3.7% | +1.8% | −1.7% | −4.3% | +2.4% | +2.4% | +1.4% | +4.7% | +0.3% | −0.7% | +3.4% | +0.4% |
| 2024 | −0.3% | +1.3% | +4.7% | −4.2% | +2.5% | −1.5% | +5.4% | +2.1% | +0.5% | −1.2% | +4.8% | −5.7% |
| 2023 | +5.3% | −2.8% | −2.0% | +1.9% | −5.2% | +5.5% | +3.1% | −3.2% | −3.4% | −3.0% | +7.1% | +5.1% |
| 2022 | +1.3% | −0.3% | +1.9% | −4.8% | +3.4% | −9.2% | +5.4% | −3.1% | −7.9% | +12.3% | +5.7% | −3.4% |
| 2021 | 0.0% | +7.2% | +6.2% | +2.8% | +2.2% | −1.5% | 0.0% | +1.2% | −1.8% | +3.5% | −4.0% | +5.7% |
| 2020 | −4.8% | −10.0% | −18.0% | +12.2% | +2.6% | −0.3% | +2.4% | +4.0% | −3.7% | −0.6% | +16.7% | +3.7% |
| 2019 | — | — | — | — | — | — | +1.0% | −5.6% | +5.1% | +1.5% | +4.4% | +3.5% |
ACLCX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 11.69%
- 3-year Sharpe ratio: 0.74 (vs 4.5% risk-free rate)
- Best month: +7.12% (Nov 2023)
- Worst month: −5.74% (Dec 2024)
ACLCX Fund Flows
Monthly money in and out of Value Fund, from SEC Form N-PORT.
- 12-month net flow: −$496.8M
- 12-month gross sales (incl. reinvestments): $373.3M
- Sales ÷ redemptions: 0.43×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $15.4M | $25.7M | −$10.3M |
| May 2026 | $10.9M | $21.1M | −$10.2M |
| Apr 2026 | $38.3M | $22.3M | $16.1M |
| Mar 2026 | $16.5M | $515.5M | −$499.0M |
| Feb 2026 | $11.9M | $37.0M | −$25.2M |
| Jan 2026 | $16.9M | $35.6M | −$18.7M |
| Dec 2025 | $189.8M | $46.6M | $143.3M |
| Nov 2025 | $14.2M | $23.7M | −$9.5M |
| Oct 2025 | $10.8M | $26.9M | −$16.2M |
| Sep 2025 | $25.9M | $26.2M | −$370K |
| Aug 2025 | $10.3M | $29.6M | −$19.3M |
| Jul 2025 | $12.5M | $59.8M | −$47.3M |
ACLCX Assets Under Management
Net assets of Value Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $1.89B |
| 2026-03-31 | $1.75B |
| 2025-12-31 | $2.21B |
| 2025-09-30 | $2.20B |
| 2025-06-30 | $2.13B |
| 2025-03-31 | $2.16B |
| 2024-12-31 | $2.12B |
| 2024-09-30 | $2.25B |
| 2024-06-30 | $2.15B |
| 2024-03-31 | $2.23B |
| 2023-12-31 | $2.14B |
| 2023-09-30 | $2.03B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.